Chemotherapy News and Research

Latest Chemotherapy News and Research

Oncolytics Biotech reports financial results for the third quarter of 2009

Oncolytics Biotech Inc. today announced its financial results for the three and nine-month periods ended September 30, 2009.

5 Nov 2009

Study suggests three-week course of radiation therapy effective for breast cancer patients

According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant side effects.

5 Nov 2009

Abraxis Health dedicates its new manufacturing facility in Phoenix

Abraxis Health, a fully-integrated personalized healthcare division of Abraxis BioScience, Inc., today announced the dedication of its new manufacturing facility in Phoenix, Arizona. The state of the art biopharma manufacturing plant represents a $70 million investment by LA-based Abraxis, and will create up to 200 high tech jobs.

5 Nov 2009

Short, intensive radiation therapy offers similar results as conventional therapy for early stage-breast cancers

5 Nov 2009

Phase III study results on miconazole Lauriad presented by BioAlliance Pharma

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).

4 Nov 2009

Combination therapy before prostate removal may prevent recurrence of cancer

Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.

4 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

Tinnitus patients need more support and advice on healthcare options

As many as one in seven people will experience tinnitus, or ringing in their ears, at some time of their life, but not enough is being done to support patients who experience this distressing condition, according to an extensive research review in the November issue of the Journal of Clinical Nursing.

4 Nov 2009

HER2-positive breast cancer patients can be treated with Trastuzumab and adjuvant radiation therapy

Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)--typically used in combination with chemotherapy.

4 Nov 2009

Some patients with tonsil cancer can be treated with radiation, says PMH study

Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation. For some patients, this may mean successful treatment with radiation alone and avoiding the side effects of chemotherapy.

4 Nov 2009

Combination of high-dose radiotherapy and chemotherapy shows encouraging results in treating LSCL

Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results, opening the door to larger scale investigation, according to new research from The University of Texas M. D. Anderson Cancer Center.

4 Nov 2009

Tonsil cancer patients harbouring HPV16 can avoid chemotherapy

4 Nov 2009

Battle with lung cancer

In his debut memoir, "No Expiration Dates: A Cancer Patient's Strategies for Survival" (published by iUniverse), Leon Weisman recounts his unique and inspirational battle with lung cancer while also offering practical advice about the emotional and social changes that a cancer diagnosis can bring to a patient as well as a family embarking on the fight to stay alive.

4 Nov 2009

Blood vessels good indicators of prostate cancer behavior

A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?

4 Nov 2009

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Nano-Cancer® therapy in patients with recurrent glioblastoma, a frequent form of brain tumor which is highly malignant. The actual study results significantly exceeded the study objective.

4 Nov 2009

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.

3 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Melanoma patients treated with radiation after surgery at lower risk of cancer recurrence

High-risk melanoma patients who are treated with radiation after surgery have a significantly lower risk of their cancer returning to the lymph nodes (19 percent), compared to those patients who do not have radiation therapy (31 percent), according to the first randomized study of its kind presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

Early tolerance of proton therapy excellent in prostate cancer patients

Proton beam therapy can be safely delivered to men with prostate cancer and has minimal urinary and rectal side effects, according to a study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009